Literature DB >> 16925699

Incidence and risk factors of Nd:YAG capsulotomy after phacoemulsification in non-diabetic and diabetic patients.

Mostafa A Elgohary1, Jonathan G Dowler.   

Abstract

PURPOSE: To estimate the cumulative incidence and identify the risk factors of posterior capsule opacification (PCO) that required Nd:YAG capsulotomy in non-diabetic and diabetic patients.
METHODS: Retrospective case-note review of 806 consecutive patients that underwent phacoemulsification and intraocular lens (IOL) implantation, 327 (40.6%) of whom were diabetic.
RESULTS: The cumulative incidence of Nd:YAG capsulotomy were 10.6%, 14.8%, 21.2% and 28.6% in non-diabetic patients; and 9%, 9.4%, 15.3% and 5.3% in diabetic patients after 1, 2, 3 and 4 years, respectively. A multivariate Cox regression analysis showed that, over the follow-up period, diabetes mellitus was associated with a decreased risk of Nd:YAG capsulotomy (hazard ratio [HR]=0.69; 95% confidence interval [CI] 0.47-0.99; P=0.047), whereas age of 65 years or younger (HR=1.58; 95% CI 1.09-2.27; P=0.02), polymethylmethacrylate (PMMA) (HR=3.98; 95% CI 1.60-9.95; P=0.003) or plate-haptic silicone IOLs (HR=3.75; 95% CI 1.60-8.80; P=0.002) in comparison with three-piece silicone IOLs, postoperative inflammation (HR=2.62; 95% CI 1.56-4.42; P<0.001) and pars plana vitrectomy (HR=1.85; 95% CI 1.20-2.83; P=0.005) were associated with an increased risk. Subgroup analysis showed that in non-diabetic patients, male gender (HR=1.63; 95% CI 1.04-2.57; P=0.03) was an additional risk factor and in diabetic patients there was no significant association between diabetes type, duration or retinopathy grade and the risk of Nd:YAG capsulotomy.
CONCLUSION: Although diabetes mellitus appears to be associated with a lower long-term incidence and a decreased risk of Nd:YAG capsulotomy, younger age, pars plana vitrectomy, postoperative inflammation, plate-haptic silicone and PMMA IOLs in addition to male gender in non-diabetic patients appear to be associated with a greater risk. Estimation of the incidence and risk factors of PCO should help in patient counselling and to design methods to reduce or prevent its development.

Entities:  

Mesh:

Year:  2006        PMID: 16925699     DOI: 10.1111/j.1442-9071.2006.01263.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  10 in total

1.  Comparison of posterior capsule opacification at 360-degree square edge hydrophilic and sharp edge hydrophobic acrylic intraocular lens in diabetic patients.

Authors:  Ling Bai; Jin Zhang; Ling Chen; Ting Ma; Hou-Cheng Liang
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Posterior capsular opacification evaluation through contrast sensitivity defocus curves with two multifocal intraocular lenses of similar material.

Authors:  Joaquín Fernández; Javier García-Montesinos; Javier Martínez; David P Piñero; Manuel Rodríguez-Vallejo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-10       Impact factor: 3.117

3.  A prospective evaluation of posterior capsule opacification in eyes with diabetes mellitus: a case-control study.

Authors:  M R Praveen; A R Vasavada; G D Shah; A R Shah; B M Khamar; K H Dave
Journal:  Eye (Lond)       Date:  2014-03-28       Impact factor: 3.775

4.  Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease.

Authors:  Ujwala S Saboo; Francisco Amparo; Hasanain Shikari; Ula V Jurkunas; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-27       Impact factor: 3.117

Review 5.  Antibody-Drug Conjugate (ADC) Research in Ophthalmology--a Review.

Authors:  Jie Shen; Mayssa Attar
Journal:  Pharm Res       Date:  2015-06-10       Impact factor: 4.200

6.  Echistatin prevents posterior capsule opacification in diabetic rabbit model via integrin linked kinase signaling pathway.

Authors:  Fengbin Lin; Yingying Chen; Hao Liang; Shaojian Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

7.  Retrospective Analyses of Potential Risk Factors for Posterior Capsule Opacification after Cataract Surgery.

Authors:  Shuang Wu; Nianting Tong; Lin Pan; Xiaohui Jiang; Yanan Li; MeiLing Guo; Hehuan Li
Journal:  J Ophthalmol       Date:  2018-08-05       Impact factor: 1.909

8.  Risk factors for the occurrence of visual-threatening posterior capsule opacification.

Authors:  Hung-Chi Chen; Chia-Yi Lee; Chi-Chin Sun; Jing-Yang Huang; Hung-Yu Lin; Shun-Fa Yang
Journal:  J Transl Med       Date:  2019-06-20       Impact factor: 5.531

9.  Nd: YAG capsulotomy for posterior capsule opacification after combined clear corneal phacoemulsification and vitrectomy.

Authors:  Ilias Georgalas; Petros Petrou; George Kalantzis; Dimitrios Papaconstantinou; Chrysanthi Koutsandrea; Ioannis Ladas
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

Review 10.  Factors Affecting Posterior Capsule Opacification in the Development of Intraocular Lens Materials.

Authors:  Grace Cooksley; Joseph Lacey; Marcus K Dymond; Susan Sandeman
Journal:  Pharmaceutics       Date:  2021-06-10       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.